ADA: Mortality Data Add To Evidence On Alogliptin’s CV Safety
This article was originally published in PharmAsia News
Executive Summary
Takeda has released new mortality data from its large-scale EXAMINE study with alogliptin, which add to the body of evidence around the cardiovascular safety of the drug amid regulatory moves and tough DDP-4 sector competition.